Abstract
Purpose To assess the patients who have had photodynamic therapy (PDT) in the Northern region of the UK, in relation to the eligibility criteria found to benefit in the TAP study (treatment of age-related macular degeneration with photodynamic therapy study), so as to make an estimate of the number of patients who might benefit from this treatment and to present the outcome of the treatment so far.
Method The records and fluorescein angiograms (FFAs) of all patients who had had PDT in the Northern region between 2001 and 2002 were reviewed for compliance with the TAP criteria of >50% classic choroidal neovascularization and >34 letters on the 2 m logMAR Early Treatment Diabetic Retinopathy Study chart. NHS funding has been available in the Northern Region since January 2001 for ‘second eye’ involvement. A review of all the angiograms performed for exudative macular degeneration in 1 year was also performed. The visual outcome of those patients 1 year from baseline was measured.
Results A total of 82 ‘second eye’ patients were treated between January 2001 and December 2002. This gives an incidence of 65 per 3 million and so about 1300 in the whole of the UK (population 60 million). In all, 238 FFAs were performed on exudative macular degeneration, with 21% being found eligible for PDT. As of February 2003, 54 TAP criteria, macular degeneration patients were 1 year from initial treatment. Of these, 12 had incomplete follow-up and 13 patients had lost more than 15 letters. The responder rate defined as losing <15 letters was 42−13/42=69%. Seven of those who did not make 1-year follow-up had lost more than 15 letters when last seen, giving a responder rate of 54−20/54=63%.
Conclusion There may not be as many patients eligible for PDT, using the TAP criteria, as previously hoped. The outcome of treatment appears similar to that found in the TAP study.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Taylor HR, Keefe JE . World blindness: a 21st century perspective. Br J Ophthalmol 2001; 85: 261–266.
Bressler NM . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: one-year results of 2 randomised clinical trials-TAP report 1. Arch Ophthalmol 1999; 117: 1329–1345.
Bressler NM . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two year results of 2 randomised clinical trials–TAP report 2. Arch Ophthalmol 2001; 119: 198–207.
Soubrane G, Bressler NM . Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of vereporfin photodynamic therapy. Br J Ophthalmol 2001; 85: 483–495.
Macular photocoagulation study group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol 1991; 109: 1242–1257.
Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–560.
Bressler NM, Gills JP . Age related macular degeneration, new hope for a common problem comes from photodynamic therapy. Br Med J 2000; 321: 1425–1427.
Mandal N, Chisholm IH . Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalomol 2002; 86: 118–119.
Kahn HA, Leibowitz HM, Ganley JP, Kini M M, Colton T, Nickerson RS et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106: 17–32.
Martinez GS, Campbell AJ, Reinken J, Allan BC . Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol 1982; 94: 181–189.
Dickinson AJ, Sparrow JM, Duke AM, Thompson JR, Gibson JM, Rosenthal AR . Prevalence of age-related maculopathy at two points in time in an elderly British population. Eye 1997; 11: 301–314.
Klein R, Klein BEK, Linton KLP . Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933–943.
Mitchell P, Smith W, Attebo K, Wang JJ . Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450–1460.
Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205–210.
Pagliarini S, Moramarco A, Wormald RPL, Piguet B, Carresi C, Balacco-Gabrieli C et al. Age-related macular disease in rural Southern Italy. Arch Ophthalmol 1997; 115: 616–622.
Klein R, Klein BEK, Cruickshanks KJ . The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res 1999; 18: 371–389.
Margherio RR, Margherio AR, DeSantis ME . Laser treatments with verteporfin and its potential impact on retinal practices. Retina 2000; 20: 325–330.
Huddad WM, Coscas G, Soubrane G . Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002; 86: 663–669.
Grey RB, Bird AC, Chisholm IH . Senile disciform macular degeneration. Features indicating suitability for photocoagulation. Br J Ophthalmol 1979; 63: 85–89.
Kaiser RS, Berger JW, William AG, Tolentino MJ, Maguire AM, Alexander J et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age related macular degeneration. Retina 2002; 22: 683–690.
Harding S . Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal. Eye 2003; 17: 119–121.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was presented in part at the Royal College of Ophthalmologists Annual Congress 2002
Rights and permissions
About this article
Cite this article
Talks, S., Setty, R. & Clarke, L. The incidence and outcome of photodynamic therapy for macular degeneration in the Northern Region of the UK. Eye 18, 588–594 (2004). https://doi.org/10.1038/sj.eye.6700709
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6700709
Keywords
This article is cited by
-
Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results
Eye (2008)
-
The presentation of data relating to visual acuity
Eye (2007)
-
Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age-Related Macular Degeneration
Japanese Journal of Ophthalmology (2006)
-
One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity
Graefe's Archive for Clinical and Experimental Ophthalmology (2006)
-
Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life
Graefe's Archive for Clinical and Experimental Ophthalmology (2006)
